# BioNTech SE clinical trials: 76 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 76 trials with BioNTech SE as lead sponsor, 24 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by BioNTech SE: 76 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/biontech-se

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 76
- Recruiting or not yet: 24
- Read on: November 19, 2026

## Trials

The 25 newest of 76, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 23, 2026 | NCT07893054 | A First-in-human Clinical Trial to Test if the Investigational Drug BNT3219 is Safe and Potentially Beneficial for People With Advanced... | BioNTech SE | Phase 1 | Not yet recruiting | Advanced Solid Tumors | 207 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893054) |
| October 21, 2026 | NCT07886684 | A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known... | BioNTech SE | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors | 173 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07886684) |
| September 1, 2026 | NCT07798648 | A Study of COVID-19 Vaccine(s) in Children and Adults | BioNTech SE | Phase 3 | Active not recruiting | COVID-19 Vaccines | 713 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07798648) |
| July 28, 2026 | NCT07730450 | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age | BioNTech SE | Phase 4 | Recruiting | COVID-19 Vaccines | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730450) |
| July 13, 2026 | NCT07698600 | A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV | BioNTech SE | Phase 1 | Recruiting | HIV -1 Infection | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07698600) |
| March 6, 2026 | NCT07455734 | Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors | BioNTech SE | Phase 1/2 | Recruiting | Advanced Solid Tumor Cancer | 533 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07455734) |
| February 6, 2026 | NCT07392372 | A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV | BioNTech SE | Phase 1 | Recruiting | HIV -1 Infection | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07392372) |
| January 30, 2026 | NCT07379580 | A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine... | BioNTech SE | Phase 2 | Recruiting | Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection | 310 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07379580) |
| January 26, 2026 | NCT07365995 | A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer | BioNTech SE | Phase 3 | Recruiting | Metastatic Castration-resistant Prostate Cancer | 736 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07365995) |
| December 24, 2025 | NCT07300839 | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age | BioNTech SE | Phase 3 | Completed | COVID-19, SARS-COV-2 Infection | 5,240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07300839) |
| December 22, 2025 | NCT07297212 | A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent... | BioNTech SE | Phase 2 | Recruiting | Recurrent Glioblastoma | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07297212) |
| December 1, 2025 | NCT07255404 | A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People... | BioNTech SE | Phase 2 | Recruiting | Pancreatic Ductal Adenocarcinoma (PDAC) | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07255404) |
| October 29, 2025 | NCT07222384 | A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at... | BioNTech SE | Phase 3 | Completed | COVID-19, SARS-COV-2 Infection | 344 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07222384) |
| September 22, 2025 | NCT07186842 | A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known... | BioNTech SE | Phase 1/2 | Recruiting | Advanced Solid Cancers | 245 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07186842) |
| September 15, 2025 | NCT07173751 | ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | BioNTech SE | Phase 3 | Recruiting | Breast Neoplasms | 558 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07173751) |
| August 29, 2025 | NCT07147348 | A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With... | BioNTech SE | Phase 1/2 | Recruiting | Advanced Solid Tumor | 375 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07147348) |
| August 8, 2025 | NCT07111520 | A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People... | BioNTech SE | Phase 1/2 | Recruiting | Non-small Cell Lung Cancer | 880 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07111520) |
| July 23, 2025 | NCT07079631 | A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment... | BioNTech SE | Phase 1/2 | Recruiting | Metastatic Colorectal Cancer | 482 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07079631) |
| July 17, 2025 | NCT07070232 | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination... | BioNTech SE | Phase 1/2 | Recruiting | Advanced Solid Tumor | 1,438 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07070232) |
| July 16, 2025 | NCT07069309 | A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years... | BioNTech SE | Phase 3 | Completed | COVID-19, SARS-COV-2 Infection | 774 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07069309) |
| April 23, 2025 | NCT06940804 | A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional... | BioNTech SE | Phase 2 | Withdrawn | Testicular Germ Cell Tumor, Extragonadal Germ Cell Tumor | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06940804) |
| March 24, 2025 | NCT06892548 | A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With... | BioNTech SE | Phase 1/2 | Recruiting | Advanced Lung Cancer | 594 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06892548) |
| February 24, 2025 | NCT06841055 | Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in... | BioNTech SE | Phase 2 | Recruiting | Non-small Cell Lung Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06841055) |
| February 14, 2025 | NCT06827236 | A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another... | BioNTech SE | Phase 1/2 | Recruiting | Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer | 380 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06827236) |
| February 11, 2025 | NCT06821061 | A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People | BioNTech SE | Phase 1/2 | Completed | Influenza, COVID-19 (Coronavirus Disease 2019) | 2,650 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06821061) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 15 |
| Phase 1/2 | 23 |
| Phase 2 | 14 |
| Phase 2/3 | 6 |
| Phase 3 | 15 |
| Phase 4 | 2 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 36 |
| Recruiting | 22 |
| Active not recruiting | 8 |
| Terminated | 6 |
| Not yet recruiting | 2 |
| Withdrawn | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| COVID-19 | 29 |
| Coronavirus Infections | 14 |
| Virus Diseases | 7 |
| Carcinoma, Non-Small-Cell Lung | 7 |
| Respiratory Tract Infections | 5 |
| Small Cell Lung Carcinoma | 4 |
| Colorectal Neoplasms | 4 |
| Influenza, Human | 4 |
| RNA Virus Infections | 4 |
| Pancreatic Neoplasms | 3 |
| Breast Neoplasms | 3 |
| Melanoma | 3 |
| Severe Acute Respiratory Syndrome | 3 |
| Lethal Congenital Contracture Syndrome 2 | 3 |
| Stomach Neoplasms | 3 |
| Neoplasm Metastasis | 3 |
| Infections | 3 |
| Coronaviridae Infections | 3 |
| Lung Diseases | 3 |
| Respiratory Tract Diseases | 3 |
| Malaria | 2 |
| Malaria, Falciparum | 2 |
| Tuberculosis | 2 |
| Neoplasms | 2 |
| Triple Negative Breast Neoplasms | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Ice suppliers in the United States](https://specstream.ai/data/businesses/ice-suppliers/united-states)
- [Shoe factory manufacturers in the United States](https://specstream.ai/data/businesses/shoe-factory-manufacturers/united-states)
- [Business office supplies and stationery companies in the United States](https://specstream.ai/data/businesses/business-office-supplies-and-stationery-companies/united-states)
- [Interior design firms in the United States](https://specstream.ai/data/businesses/interior-design-firms/united-states)
- [Specialized medical facilities in the United States](https://specstream.ai/data/businesses/specialized-medical-facilities/united-states)
- [Caterers in the United States](https://specstream.ai/data/businesses/caterers/united-states)
